Before revision: De novo therapeutic design is challenged by a vast chemical repertoire and multiple constraints such as high broad-spectrum potency and low toxicity.
After revision: De novo therapeutic design is challenged by a vast chemical repertoire and multiple constraints , e.g., high broad-spectrum potency and low toxicity.